Rheumatic Heart Disease (RHD) — Comprehensive Research Report

Prepared to populate a disease-knowledge-base entry (pathophysiology graph, phenotype/gene/treatment annotations). Ontology term suggestions are given as best-effort identifiers; because AI-suggested ontology IDs are known to be occasionally wrong, curators should verify every ID/label pair against the authoritative ontology (OAK/OLS) before committing — this report flags terms with lower confidence explicitly.

1. Disease Information

Overview. Rheumatic heart disease (RHD) is the chronic, permanent cardiac valvular damage that results from one or more episodes of acute rheumatic fever (ARF), itself a delayed, non-suppurative autoimmune sequela of mucosal (pharyngeal, and increasingly recognized skin) infection with Group A Streptococcus (GAS, Streptococcus pyogenes) in a genetically susceptible host. ARF is a multisystem inflammatory illness (joints, heart, CNS, skin, subcutaneous tissue); RHD is specifically the residual, usually left-sided, valvular fibrosis/scarring that persists after the acute inflammatory episode(s) resolve. A single severe ARF episode, and more often recurrent episodes, converts initially reversible valvulitis into fixed valve damage — chiefly mitral, then aortic, disease (WHO fact sheet; StatPearls).

Key identifiers: - ICD-10-CM: I00–I02 (acute rheumatic fever, incl. I01. "rheumatic fever with heart involvement"); I05–I09 (chronic rheumatic heart diseases — I05 mitral valve diseases, I06 aortic valve diseases, I07 tricuspid valve diseases, I08 multiple valve diseases, I09 other/unspecified rheumatic heart disease, incl. I09.81 rheumatic heart failure, I09.9 unspecified) (icd10data.com). - MONDO / OMIM / Orphanet: RHD and ARF have MONDO terms integrating DOID/OMIM/Orphanet mappings; exact CURIEs should be confirmed via mondo.monarchinitiative.org lookup before curation (not independently verified in this research pass — flag for OAK confirmation rather than assume a specific numeric ID). - MeSH: "Rheumatic Heart Disease" (D012214); "Rheumatic Fever" (D012213). - Synonyms:* chronic rheumatic valvular heart disease; post-streptococcal valvulitis; rheumatic valve disease; (historical) rheumatic mitral stenosis/regurgitation, rheumatic aortic stenosis/regurgitation as organ-specific labels.

Evidence base character: RHD knowledge is drawn from a mix of aggregated disease-level resources (Global Burden of Disease modeling, national/regional registries such as Australia's RHD registers, WHO fact sheets) and individual-patient data (echocardiographic screening cohorts, hospital case series, and increasingly EHR-linked data in Australia/NZ). Genetic association data come from case-control and GWAS cohorts (South Asia, Aboriginal Australia, sub-Saharan Africa, Brazil, Uganda).

2. Etiology

Primary causal chain: GAS pharyngeal (± skin) infection → in a genetically susceptible host, an aberrant, cross-reactive humoral and cellular immune response → ARF (which may include carditis) → in a subset, and especially with recurrent episodes, permanent valvular fibrosis (RHD). This is fundamentally an infection-triggered autoimmune disease, not a direct infective process of the valve (GAS itself is not found in the damaged valve tissue).

Risk factors

Environmental/host risk factors (WHO; Indigenous HPF): - Poverty, household crowding, and reduced access to healthcare — the dominant social determinants, driving both the incidence of untreated GAS pharyngitis and delayed diagnosis/inadequate secondary prophylaxis. - Age 5–14 years for first ARF episode (peak susceptibility window). - Prior episode(s) of ARF (single strongest risk factor for recurrence/progression — each recurrence compounds valve damage). - Crowded living conditions facilitating GAS transmission (households, boarding schools, remote communities). - Possibly skin GAS infection (impetigo/scabies-associated) as an under-recognized trigger, particularly implicated in some high-burden tropical settings.

Genetic risk factors (see §4 for detail): HLA class II alleles (HLA-DR/DQ), a novel HLA class III susceptibility locus, and candidate non-HLA loci including the immunoglobulin heavy-chain locus (IGHV4-61 region) (Nature Reviews Cardiology genetics review; Sci Rep 2020, PMC7265443).

Protective factors: No robust genetic protective variant is well established; the principal modifiable protective interventions are behavioral/health-system (see §13) rather than intrinsic biological protection. Some HLA alleles show consistent negative (protective) association across cohorts in individual studies, but replication across ancestries is inconsistent (Circulation 1999).

Gene–environment interaction: The core G×E interaction is between host HLA class II genotype (governing which streptococcal/self peptide epitopes are presented to CD4+ T cells) and the degree/recurrence of GAS exposure (itself environmentally/socioeconomically determined) — repeated antigenic exposure in a susceptible HLA background is thought to drive epitope spreading and progressively severe autoimmune valvulitis.

3. Phenotypes

RHD/ARF phenotypes span acute (ARF) manifestations and chronic valvular (RHD) manifestations.

Acute rheumatic fever manifestations (Jones criteria major/minor)

Table (click to expand)

Phenotype	Frequency	Notes	Suggested HPO
Carditis (endocarditis/valvulitis, ± myocarditis, ± pericarditis)	Most commonly reported major criterion; subclinical carditis detectable by echo even without murmur	Mitral valve most frequent/severe, then aortic	HP:0001635 (heart failure, if decompensated); HP:0001653 (mitral regurgitation); HP:0001659 (aortic regurgitation)
Migratory polyarthritis	Very common major criterion, classically large joints	Fleeting, asymmetric, exquisitely aspirin-responsive	HP:0001369 (arthritis)
Sydenham chorea	10–30% of ARF cases; sole finding in ~20% (MedLink/StatPearls search summary)	Delayed onset 1–8 months post-GAS; 60–80% have concurrent cardiac involvement	HP:0002072 (chorea)
Erythema marginatum	<6% of cases	Serpiginous, migratory, trunk/limb-sparing face	HP:0025590 or search HPO "erythema marginatum"
Subcutaneous nodules	<10% of cases	Firm, painless, over extensor surfaces; almost always co-occurs with carditis	HP:0001482 (subcutaneous nodule)
Fever	Minor criterion	—	HP:0001945
Arthralgia	Minor criterion (cannot double-count with major arthritis)	—	HP:0002829
Elevated ESR/CRP	Minor criterion	Reflects systemic inflammation	HP:0011227 / HP:0011227-adjacent
Prolonged PR interval	Minor criterion	ECG finding	HP:0011703

2015 revised Jones criteria stratify by population risk (low-risk vs. moderate/high-risk, the latter ARF incidence >2/100,000 children/year), formally incorporate Doppler echocardiography for subclinical carditis detection, and treat isolated chorea or indolent carditis as presumptive ARF without requiring other criteria (Gewitz et al., Circulation 2015, PMID 25908771; AAP 2024 specificity analysis).

Chronic RHD manifestations

Mitral regurgitation (earliest, most common lesion; HP:0001653) and mitral stenosis (later, from progressive leaflet thickening/fusion; HP:0001718).
Aortic regurgitation (HP:0001659) and aortic stenosis (HP:0001650), typically less frequent/severe than mitral disease and rarely isolated.
Tricuspid regurgitation, usually functional/secondary to pulmonary hypertension from left heart disease.
Atrial fibrillation (HP:0005110), often from left atrial enlargement in mitral stenosis — a major driver of thromboembolic stroke risk.
Congestive heart failure (HP:0001635) — dyspnea, edema, orthopnea; often the presenting symptom since chronic RHD is frequently asymptomatic until decompensation.
Pulmonary hypertension (HP:0002092), secondary to chronic left-sided valvular disease.
Infective endocarditis risk elevated on damaged valves.
Stroke/systemic embolism from atrial fibrillation or valve-associated thrombus.

Age of onset: ARF classically presents in school-age children (5–14 yrs); first presentation of RHD (often with a murmur or heart-failure symptoms) may not occur until years later, sometimes not until young adulthood, because chronic RHD is frequently asymptomatic ("latent") until echocardiographic screening or heart failure onset (news-medical.net pathophysiology summary).

Severity/progression pattern (from a prospective severity-progression cohort, JAHA 2017, Multi-State Model, PMID 28255075): - Severe RHD at diagnosis: rapid progression, 50% require surgery within 2 years, 10% die within 6 years. - Moderate RHD: mixed — roughly one-third each progress to severe, remain moderate, or regress to mild over 10 years. - Mild RHD: most favorable — >60% remain mild at 10 years; ~10% become "inactive."

Quality of life: Chronic heart failure, activity limitation, recurrent hospitalization, anticoagulation burden (bleeding risk, INR monitoring), pregnancy risk, and the psychosocial burden of lifelong monthly intramuscular penicillin injections (frequently reported as painful, with poor long-term adherence) all substantially affect QoL, particularly in adolescents and young adults in endemic, resource-limited settings.

4. Genetic/Molecular Information

RHD/ARF is not a monogenic Mendelian disease — it is a complex, polygenic, infection-triggered autoimmune condition with strong immunogenetic (HLA) contribution.

Causal/major-effect loci — HLA class II and III: - HLA-DR and HLA-DQ alleles (class II) show the most consistent associations across African, South Asian, and Latin American cohorts (Nat Rev Cardiol genetics review; Uganda case-control, PMC3943278; Brazil, PMID 2040052). - A GWAS in South Asians (India/Fiji; 672 cases, 491 controls) replicated in a UK Biobank European follow-up (150 cases, 1,309 controls) identified a novel susceptibility signal in the HLA class III region (rs201026476; combined OR 1.81, 95% CI 1.51–2.18, P = 3.48×10⁻¹⁰) (Sci Rep 2020, PMC7265443). - Earlier GWAS work implicated the HLA-DQA1–HLA-DQB1 region and, notably, the immunoglobulin heavy-chain locus (chromosome 14, including the IGHV4-61 gene segment) — supporting a B-cell/antibody-response contribution to susceptibility, consistent with the molecular-mimicry model (biorxiv/GWAS Aboriginal Australians).

Suggested HGNC genes for annotation: HLA-DRB1, HLA-DQA1, HLA-DQB1, IGHV4-61 (contributing locus). Curators should bind via HGNC where a stable symbol exists (HLA genes are commonly annotated at the allele/serotype level rather than single HGNC IDs; verify convention).

Functional impact: These are susceptibility/modifier alleles (not classic pathogenic variants) — appropriate relationship_type is SUSCEPTIBILITY, and inheritance is best modeled as polygenic/complex (HP:0010982-style, if adapting the dismech Inheritance slot) rather than monogenic Mendelian, given no single-gene causal variant explains most cases.

Epigenetics: No well-established disease-specific epigenetic signature has been robustly replicated; this remains an evidence gap.

Chromosomal abnormalities: None reported — RHD is not associated with aneuploidy or structural chromosomal rearrangement; it is a complex autoimmune trait.

Molecular target of the autoimmune response (the "antigen" side): cardiac myosin (α-myosin heavy chain), valve endothelial/interstitial proteins including laminin, collagen IV, cardiac myosin, tropomyosin, keratin, and vimentin, plus the CAR (coxsackievirus-adenovirus receptor) and β1-adrenergic receptor (β1AR) as proposed valve-endothelial/cardiomyocyte targets of cross-reactive antibody (PMC4137453, "Rethinking Molecular Mimicry"). Suggested UniProt/HGNC anchors: MYH6 (cardiac myosin heavy chain, alpha), VIM (vimentin), LAMA2/laminin family, COL4A1 and related collagen IV genes, ADRB1 (β1-adrenergic receptor).

5. Environmental Information

Infectious trigger: Streptococcus pyogenes (Group A Streptococcus), primarily via pharyngeal infection; skin infection (impetigo) is an increasingly recognized alternative/contributing portal in some high-incidence tropical settings. NCBITaxon: NCBITaxon:1314 (Streptococcus pyogenes).
Socioeconomic/environmental risk factors: overcrowded housing, poverty, limited access to primary healthcare and diagnostic microbiology, and reduced access to secondary prophylaxis programs are the dominant modifiable environmental determinants — these explain most of the geographic and Indigenous-population disparity in disease burden (see §9) (Far North Queensland temporospatial study, PLOS NTD).
Lifestyle factors: No specific diet/exercise/substance-use risk modifiers are established beyond the crowding/transmission pathway above; adherence behavior to secondary prophylaxis is itself a major modifiable "environmental" determinant of RHD progression.
ECTO/exposure-term candidates: exposure to overcrowded housing; exposure to Streptococcus pyogenes (a term for GAS mucosal/skin exposure).

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

GAS mucosal (pharyngeal ± skin) infection in a genetically susceptible (HLA class II/III) host.
Molecular mimicry / cross-reactive immune priming: The GAS group A carbohydrate epitope (N-acetyl-glucosamine on a rhamnose backbone) and the α-helical coiled-coil M protein structurally mimic host cardiac and connective-tissue antigens — cardiac myosin, laminin, collagen IV, vimentin, tropomyosin, keratin — plus CAR and β1AR on valve endothelium/cardiomyocytes (PMC4137453; PMID 16455580).
B-cell response: cross-reactive antibody (initially IgM, later IgG) is produced against GAS carbohydrate/M-protein epitopes and binds valve endothelium, up-regulating VCAM-1 and promoting inflammatory cell recruitment (Frontiers 2025 pathogenesis review, PMC12018407).
CD4+ T-cell response: CD4+ T lymphocytes, exhibiting a "degenerate" (cross-reactive/promiscuous) pattern of antigen recognition, infiltrate valve tissue and myocardium and are considered the prime effector cells of chronic valvular damage; Th1-skewed, IFN-γ-driven inflammation predominates.
Acute valvulitis/carditis: endothelial activation and immune-cell infiltration produce Aschoff bodies — granulomatous foci of central fibrinoid necrosis surrounded by lymphocytes, plasma cells, macrophages, and pathognomonic Anitschkow cells (activated macrophages with a distinctive "caterpillar"-like linear chromatin pattern) (Wikipedia/Grokipedia histopathology summary; pathology reference PEIR).
Chronic remodeling: repeated/persistent inflammation drives valve leaflet fibrosis, neovascularization (abnormal thick-walled vessels within normally avascular valve tissue), leaflet thickening, commissural fusion, and dystrophic calcification — converting reversible acute valvulitis into fixed stenosis and/or regurgitation, predominantly mitral > aortic > tricuspid.
Hemodynamic/organ-level consequences: valve dysfunction → left atrial enlargement → atrial fibrillation and thrombus formation → stroke/systemic embolism; and/or → pulmonary venous congestion → pulmonary hypertension → right heart failure; and/or → ventricular volume/pressure overload → congestive heart failure.

Cell types involved (candidate CL terms — verify via OAK): CD4+ T lymphocyte (CL:0000624), Th1 cell (CL:0000545), B lymphocyte / plasma cell (CL:0000236 / CL:0000786), macrophage (CL:0000235), activated/"Anitschkow" macrophage (no dedicated CL term — annotate as macrophage with a descriptive qualifier), valve endothelial cell (CL:0000115 generic endothelial cell, or a valve-specific subtype if available), valve interstitial fibroblast (CL:0000057 fibroblast).

Biological processes (candidate GO terms): antigen processing and presentation (GO:0019882), T-cell mediated cytotoxicity (GO:0001913), complement activation (GO:0006956), acute inflammatory response (GO:0002526), positive regulation of leukocyte cell-cell adhesion / VCAM-1-mediated adhesion (GO:1903039-family), fibrosis-related extracellular matrix remodeling processes (as used elsewhere in the KB's fibrotic_response module).

Relationship to existing dismech mechanism modules: RHD is a strong candidate to conforms_to the fibrotic_response module (chronic valvulitis → mesenchymal/valve interstitial cell activation → excessive ECM deposition → organ [valve] dysfunction), the cardiomyopathy_maladaptive_remodeling module if ventricular remodeling/heart failure nodes are curated, and cardiac_ion_channel_repolarization is not the right fit for the AF here (RHD-associated AF is structural/left-atrial-enlargement-driven, not a primary channelopathy) — model AF as a downstream structural consequence rather than conforming to that module. The granulomatous Aschoff-body lesion itself may be a candidate for an "Xogenesis"-style pathological-structure-formation node (a defined pathological granulomatous body, analogous to the granuloma_formation module's macrophage-fusion pattern, though Aschoff bodies are histologically and immunologically distinct from infectious/mycobacterial granulomas and a new/adapted anchor would be needed rather than direct conformance).

Molecular profiling / omics: RHD mechanistic omics data are comparatively sparse relative to other cardiovascular diseases; most mechanistic evidence derives from immunohistochemistry of excised valve/appendage tissue, serologic/antibody studies, and the Lewis-rat model transcriptome/histology (see §15) rather than large-scale human transcriptomic/proteomic atlases. This is a notable evidence gap relative to better-profiled cardiovascular conditions.

7. Anatomical Structures Affected

Organ level: - Primary: heart valves — mitral valve (most common and most severely affected; UBERON candidate: UBERON:0002094 mitral valve or generic UBERON:0002136/verify), aortic valve (UBERON:0002137-family, verify), less commonly tricuspid valve, rarely pulmonary valve. - Secondary/associated in ARF (not RHD per se): joints (synovium, UBERON:0000980 synovial joint) in migratory polyarthritis; basal ganglia/caudate-putamen (UBERON:0002420 basal ganglia region) in Sydenham chorea; skin/subcutaneous tissue in erythema marginatum and subcutaneous nodules; pharynx (UBERON:0000165) as the primary infection site. - Body systems: cardiovascular (primary), musculoskeletal (ARF arthritis), nervous (ARF chorea), integumentary (ARF skin findings), and secondarily respiratory (pulmonary hypertension/congestion from left heart disease).

Tissue/cell level: valve leaflet fibrous layer, valve endothelium, myocardial interstitium (Aschoff bodies classically myocardial/subendocardial), pericardium (pericarditis in severe carditis). Cell populations: valve endothelial cells, valve interstitial fibroblasts, infiltrating CD4+ T cells, macrophages/Anitschkow cells, plasma cells.

Subcellular: no disease-defining subcellular organelle lesion (this is an extracellular-matrix/immune-infiltrate disease rather than an organellopathy); GO Cellular Component annotations would center on extracellular matrix (GO:0031012) and cell surface/plasma membrane VCAM-1 (GO:0009986 cell surface) rather than intracellular compartments.

Localization/laterality: left-sided valves (mitral, then aortic) affected far more often and more severely than right-sided valves — a consistent, mechanistically notable asymmetry attributed to higher hemodynamic shear stress on the left side of the heart amplifying endothelial activation/antibody deposition.

8. Temporal Development

Onset: ARF typically presents in school-age children (5–14 years), 1–5 weeks after GAS pharyngitis (except Sydenham chorea, which can be delayed 1–8 months). Chronic RHD may not become clinically apparent (murmur, symptoms) until years to decades later; latent RHD (echocardiographically detectable, subclinical) is a recognized and common intermediate state, especially in endemic screening cohorts.
Progression pattern: Variable and stage-dependent (see severity data in §3): mild disease is often stable/regressive; moderate disease shows a roughly even three-way split (progress/stable/regress) over a decade; severe disease at diagnosis progresses rapidly, with a high 2-year surgical intervention rate and appreciable 6-year mortality (JAHA multi-state model, PMID 28255075).
Disease course: classically episodic-to-progressive — each ARF recurrence adds incremental, cumulative valvular damage; disease is not typically "relapsing-remitting" in the neurological sense but rather step-wise worsening punctuated by inflammatory flares (ARF recurrences), against a background of gradually progressive valvular fibrosis/calcification even in inflammation-free intervals.
Remission: acute inflammatory episodes (arthritis, fever, even carditis) can resolve completely, especially with anti-inflammatory treatment; however, once structural valve fibrosis/scarring has occurred it is not reversible — "regression" documented in mild latent RHD cohorts likely reflects resolution of reversible valvulitis/edema rather than true fibrotic reversal.
Critical intervention window: primary prevention (antibiotic treatment of GAS pharyngitis within 9 days of symptom onset) reliably prevents the first ARF episode; secondary prophylaxis initiated promptly after a first ARF episode, and sustained for years, is the critical window for preventing the cumulative valvular damage that defines RHD.

9. Inheritance and Population

Epidemiology (Global Burden of Disease 2021): - ~40.5 million people affected globally; ~306,000–373,000 deaths annually (~2% of all cardiovascular deaths) (WHO; GBD pediatric RHD 2021, PMC12293350). - ~3.85 million new RHD cases in 2021; global age-standardized incidence rate rose modestly from 55.84 to 66.76 per 100,000 (1990→2021), while age-standardized death rate in children fell ~74% and DALY rate fell from 117.22 to 41.56 per 100,000 over the same period — a "declining severity, persistent/rising incidence, widening inequality" pattern (GBD pediatric analysis, PMC12293350). - Historical benchmark: 1990–2015 GBD estimated 319,400 RHD deaths globally in 2015 (NEJM 2017, PMID 28834488). - Highest incidence in children aged 0–14, concentrated in low- and middle-income countries.

Inheritance pattern: Multifactorial/polygenic, infection-dependent — not a Mendelian single-gene disorder. HLA-associated susceptibility with modest individual-allele effect sizes (e.g., OR ~1.8 for the HLA class III GWAS hit), consistent with a complex trait requiring an environmental (GAS exposure) trigger. No described penetrance/expressivity framework analogous to monogenic disease; no genetic anticipation or germline mosaicism relevance; no described founder-effect variant, though population-specific HLA allele frequencies likely contribute to regional prevalence differences.

Population demographics and geographic distribution: - Highest global rates: sub-Saharan Africa, followed by Aboriginal and Torres Strait Islander Australians, Māori and Pacific Islanders, and South Asia. - Australia (Indigenous disparity): First Nations Australians are ≥60 times more likely to experience ARF/RHD than non-Indigenous Australians; the Northern Territory has one of the highest documented RHD prevalence rates worldwide (~3,005 per 100,000 Indigenous residents). Indigenous communities account for 78% of all RHD cases and 92% of all ARF cases in Australia (2022 data). Mortality rate ratio (Indigenous vs. non-Indigenous), 2013–2017: 15.9 (Excess Deaths, PMC10756360; Indigenous HPF). In Far North Queensland, RHD incidence rose from 4.7 to 49.4 per 100,000/year (1997→2017); 2017 prevalence was 12/1000 Indigenous vs. 2/1000 non-Indigenous (PLOS NTD). - Māori/Pacific Islander (NZ): cumulative ARF hospitalization risk by age 13 is approximately 1 in 150. - Sex ratio: GBD 2021 data indicate women represent just over half of global RHD cases; some regional/age-specific variation exists (e.g., possible sex differences in Sydenham chorea susceptibility) but no large, uniform sex skew is established for ARF susceptibility itself. - Consanguinity/carrier frequency: not applicable in the classic Mendelian sense (complex trait); HLA allele-frequency variation across ancestries is the relevant population-genetic parameter rather than a carrier-frequency concept.

10. Diagnostics

Clinical/serologic tests: - Evidence of preceding GAS infection: throat culture/rapid antigen test (acute infection); anti-streptolysin O (ASOT) — sensitivity ~80% (adult cutoff >240 Todd units, child >320); anti-DNase B — sensitivity ~90%, complementary to ASOT (paired/sequential titers recommended for optimal sensitivity) (search summary of Frontiers 2021, "Holy Grail" review). - Inflammatory markers: ESR and CRP — elevated as ARF minor criteria; positively correlate with ASOT; may help monitor transition from acute carditis toward chronic RHD. - Electrocardiography: prolonged PR interval (minor Jones criterion); atrial fibrillation detection in chronic disease. - Echocardiography (the central chronic-disease diagnostic modality): 2D + continuous-wave + color-Doppler echo per the 2012 World Heart Federation (WHF) criteria, which classify findings into "definite RHD" (4 subcategories), "borderline RHD" (3 subcategories), and "normal", with age-based modifications for those >20 years — designed to standardize detection of latent/subclinical disease for enrollment into secondary-prophylaxis programs (Reményi et al., Nat Rev Cardiol 2012, PMID 22371105; WHF PDF). Simplified screening criteria have since been validated to predict progression of latent disease (Circ Cardiovasc Imaging, search summary). - Histopathology (rarely obtained clinically; mainly surgical/autopsy specimens): Aschoff bodies and Anitschkow cells in active carditis; chronic valve leaflet fibrosis, neovascularization, and dystrophic calcification in end-stage disease.

Genetic testing: RHD is not currently subject to clinical genetic testing — there is no validated single-gene, panel, or polygenic-risk-score test used in patient management; genetic association findings (HLA, IGH locus) remain research-stage.

Clinical diagnostic criteria: Revised (2015) Jones criteria, risk-stratified by population ARF incidence, incorporating echocardiography and presumptive-ARF categories for isolated chorea/indolent carditis/recurrence (Gewitz et al. 2015, PMID 25908771). Differential diagnosis of ARF includes reactive arthritis, septic arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus, viral myocarditis/pericarditis, infective endocarditis, and (for chorea) other movement disorders (tic disorders, Huntington disease in adults, drug-induced chorea).

Screening: Active echocardiographic screening programs in endemic/high-risk populations (e.g., Australia, Pacific, sub-Saharan Africa) using WHF criteria to detect latent RHD before clinical presentation, enabling early enrollment in secondary prophylaxis — though the clinical/cost-effectiveness value of screening asymptomatic borderline disease remains an area of active debate (Nat Rev Cardiol WHF criteria paper; Global Heart 2023 review of WHF criteria performance).

11. Outcome/Prognosis

Mortality: GBD 2021 attributes ~306,000–373,000 deaths/year to RHD globally; nearly 2% of all cardiovascular deaths. Pediatric age-standardized RHD death rate fell ~74% from 1990–2021, reflecting improved secondary prophylaxis and surgical access in many settings, but absolute burden remains high in under-resourced regions.
Survival by severity at diagnosis (JAHA 2017 multi-state model):
Severe RHD: 50% require surgery within 2 years; 10% die within 6 years.
Moderate RHD: ~1/3 progress to severe, ~1/3 stable, ~1/3 regress to mild over 10 years.
Mild RHD: >60% remain mild at 10 years; ~10% become inactive.
Disability burden: RHD causes the highest DALYs of any cardiovascular disease among 10–14-year-olds globally — reflecting its unique concentration in children/young people relative to other, older-onset cardiovascular conditions.
Complications driving morbidity: progressive heart failure, atrial fibrillation, cardioembolic stroke, infective endocarditis, pulmonary hypertension, and — in higher-resource settings — the risks/burdens of anticoagulation and prosthetic valve surgery (thromboembolism ~11% cumulative incidence over 25 years post-mechanical mitral valve replacement in one cohort; rising rates of intracranial hemorrhage, perivalvular leak, and infective endocarditis over time on mechanical valves — search summary of valve-surgery outcome literature).
Prognostic factors: severity of carditis at first presentation is the single strongest prognostic determinant; timely secondary prophylaxis adherence, access to echocardiographic monitoring, and access to timely valve surgery in low-resource settings are the major modifiable prognostic levers.

12. Treatment

Pharmacotherapy — acute rheumatic fever

Aspirin (CHEBI:15365) — first-line anti-inflammatory for arthritis/mild carditis; 50–60 mg/kg/day, tapered over 1–2 weeks after symptom resolution.
NSAIDs (e.g., naproxen, CHEBI:7476) — endorsed alternative to aspirin with comparable efficacy and fewer GI side effects in comparative pediatric trials.
Corticosteroids (e.g., prednisone/prednisolone, CHEBI:8382) — reserved for moderate-to-severe carditis; a Cochrane systematic review found no robust evidence that anti-inflammatory treatment (steroids or aspirin) prevents or reduces long-term cardiac valve damage, despite symptomatic benefit (Cilliers et al., Cochrane 2015) — an important evidence caveat for curation (treat as symptomatic, not disease-modifying for valve outcome).

Antibiotic therapy (both eradication and secondary prophylaxis)

Benzathine penicillin G (BPG), CHEBI (verify exact CURIE for the benzathine salt) — the cornerstone of both (a) eradication of the inciting GAS infection and (b) secondary prophylaxis: standard dosing is 1.2 million units (900 mg) deep IM every 3–4 weeks for a minimum of 5 years, often extended to age 21 or 10 years post-ARF episode (regimen duration guidance varies by carditis severity per AHA/WHO guidance) (AAC 2023 phase 1 PK study, PMC10720493).
Adherence challenge: dosing frequency and injection pain drive suboptimal real-world adherence; a subcutaneous high-dose BPG infusion formulation is under phase 1 investigation to allow less-frequent dosing (PMC10720493).
Primary prevention: oral penicillin V or single-dose IM BPG for confirmed/probable GAS pharyngitis, started within 9 days of symptom onset, reduces ARF attack rate by ~70% (meta-analysis, PMID 15927077); macrolides/cephalosporins are penicillin-allergy alternatives.
Penicillin allergy in severe RHD is a specific clinical challenge addressed by a dedicated AHA presidential advisory on desensitization/testing strategies (JAHA 2022).

Anticoagulation (chronic RHD with AF or mechanical valve)

Warfarin (CHEBI:10033), target INR 2–3, remains standard for RHD-associated atrial fibrillation — a landmark trial (INVICTUS) established warfarin's superiority over DOACs specifically in RHD-associated AF, a population historically excluded from DOAC trials (NEJM editorial, PMID/DOI 10.1056/NEJMe2210187).
Pregnancy-specific management: warfarin crosses the placenta and risks fetal warfarin syndrome (nasal hypoplasia, skeletal abnormalities) in the first trimester; low-molecular-weight heparin (LMWH, dose-adjusted to anti-Xa 0.5–1.0 U/mL) or unfractionated heparin is preferred peripartum, with heparin bridging around delivery and resumption of warfarin postpartum.

Interventional/surgical

Percutaneous balloon mitral valvuloplasty (PBMV) — preferred for suitable (non-calcified, non-regurgitant) rheumatic mitral stenosis; less invasive, shorter procedure, lower cost than surgery, with comparable mid-term outcomes in appropriately selected patients; ~20% develop new/worsened mitral regurgitation post-procedure.
Mitral valve repair vs. replacement — repair shows greater hemodynamic improvement and short-term clinical efficacy where anatomically feasible; replacement (mechanical or bioprosthetic) is required for more advanced/calcified/regurgitant disease. Mechanical valve replacement carries long-term thromboembolism (~11% cumulative at 25 years in one cohort), intracranial hemorrhage, perivalvular leak, and endocarditis risk requiring lifelong anticoagulation.
NCIT candidate treatment terms (verify exact IDs via OAK): NCIT:C15986 Pharmacotherapy (generic anchor for aspirin/NSAID/steroid/penicillin/warfarin, paired with therapeutic_agent); NCIT:C15329 Surgical Procedure (mitral/aortic valve repair or replacement); a balloon-valvuloplasty-specific NCIT term should be looked up directly (not confidently identified in this pass).

Prevention of complications / supportive care

Standard heart-failure pharmacotherapy (diuretics, ACE inhibitors/ARBs, beta-blockers) is used symptomatically for RHD-related heart failure, following general heart-failure guidelines rather than RHD-specific evidence — these represent generic HF pharmacotherapy rather than RHD-mechanism-targeted treatment and should be annotated as treatment_term: NCIT:C15986 Pharmacotherapy with the appropriate agent, not target_mechanisms on the autoimmune valvulitis pathway itself.

Experimental

No RHD-specific advanced therapeutics (gene therapy, cell therapy, targeted immunotherapy) are in clinical development at this time; the major "experimental" frontier is primary prevention via GAS vaccine (§13) rather than disease-modifying treatment of established RHD.

13. Prevention

Primary prevention: prompt antibiotic treatment (penicillin) of confirmed/probable GAS pharyngitis — ~70% reduction in ARF attack rate (PMID 15927077; AHA 2009 statement). Population-level "sore throat management" programs (school-based throat-swab/treat programs) are a core public-health strategy in endemic regions.

Secondary prevention: regular BPG secondary prophylaxis after a confirmed ARF episode, sustained for years (minimum 5, often to age 21+ or longer for those with carditis/RHD) — the single most impactful intervention for preventing RHD progression once ARF has occurred.

Tertiary prevention: infective-endocarditis prophylaxis considerations for high-risk dental/surgical procedures in patients with damaged valves (per current, more restrictive endocarditis-prophylaxis guidelines); anticoagulation to prevent thromboembolic stroke in RHD-associated AF; timely surgical referral to prevent irreversible heart-failure decompensation.

Vaccination (the major prevention frontier): No licensed GAS vaccine currently exists. Active development includes: - Carbohydrate-based (L-rhamnose/group A carbohydrate backbone) candidates designed to raise protective IgG without inducing cross-reactive (cardiac-mimicking) antibody — directly addressing the historical safety concern that a poorly designed GAS vaccine could itself trigger molecular-mimicry-driven carditis (F1000Research/PMC11829149; PMID 39959434). - Peptide-based candidates — phase 1 RCT ongoing/recently completed (est. completion March 2025) (Trials journal, 2024). - IVI universal conjugate vaccine program — proof-of-concept study launched 2024, running through 2027, aiming to select an optimal conjugation platform via animal immunogenicity/efficacy studies (IVI). - WHO R&D Technology Roadmap / Preferred Product Characteristics for GAS vaccines formally guides the development pipeline (Clin Infect Dis 2019, PMID 30624673). - A dedicated cardiac-safety monitoring framework (endorsed by SAVAC/ASAVI) has been developed specifically for early-phase GAS vaccine trials, given the historical precedent of vaccine-associated ARF risk, standardizing echocardiographic + clinical cardiac surveillance (PMID 40450801).

Public health/behavioral interventions: overcrowding reduction, health-system strengthening for GAS pharyngitis diagnosis/treatment access, and community-based ARF/RHD control programs (notably in Aboriginal/Torres Strait Islander Australian communities) — a recent systematic review catalogued Australian RHD-elimination prevention programs and their implementation gaps (Lowitja Journal 2024).

Genetic counseling / risk stratification: not applicable in the classic monogenic sense; population/community-level risk stratification (Indigenous status, remoteness, prior ARF history) drives targeted screening and prophylaxis-program enrollment rather than individual genetic counseling.

14. Other Species / Natural Disease

RHD is, for practical purposes, a human-specific disease — S. pyogenes is essentially a human-adapted pathogen, and there is no well-documented naturally occurring veterinary/wildlife analog of GAS-triggered post-infectious autoimmune carditis. No OMIA (animal Mendelian disease) entry or established veterinary RHD analog was identified in this search. This is a notable contrast to many other cardiovascular/autoimmune diseases in the dismech KB that have companion-animal natural-disease correlates — for RHD, the "other species" content is essentially limited to laboratory-induced models (§15) rather than spontaneous natural disease. No zoonotic transmission concern applies (GAS pharyngitis/ARF pathogenesis is human-host-restricted in practice, notwithstanding rare GAS colonization reports in other mammals).

15. Model Organisms

Lewis rat — the primary, best-validated model (Animal Models review, PMC4220098 / PMID 25414841; AJP epitope-mapping study): - Female Lewis rats (8–12 weeks) immunized subcutaneously with recombinant GAS M5 protein (or M5 peptide) in complete Freund's adjuvant, with Bordetella pertussis as additional adjuvant and a day-7 booster, develop autoimmune valvulitis recapitulating human histopathology. - Outcomes: 75% develop rheumatic-like myocarditis, 62.5% develop chronic valvulitis by 24 weeks post-immunization, with cross-reactive heart-tissue antibodies and T cells, and histological findings including acute damage progressing to fibrosis and vascular neogenesis — closely mirroring the human chronic valve lesion. - Cardiac myosin immunization (rather than M protein) also induces valvulitis in Lewis rats, with the pathogenic epitopes mapped to the myosin rod region, supporting the molecular-mimicry model directly. - An alternative formalin-killed streptococci induction protocol has also been reported to produce chronic rheumatic valvulitis (PMID referenced via search: "An animal model of chronic rheumatic valvulitis induced by formalin-killed streptococci"). - A 2025 Nature Reviews Cardiology commentary describes a "transformative preclinical model" development, suggesting active ongoing refinement of RHD animal modeling as of this reporting period (title only identified; full mechanistic detail not retrieved in this pass — recommend direct follow-up read: Nat Rev Cardiol 2025).

Model limitations: Rodent models require artificial immunization (adjuvant-driven) rather than natural GAS mucosal infection, so they model the downstream autoimmune effector phase well but do not fully recapitulate the natural infection-to-autoimmunity transition, repeated-exposure/recurrence biology, or the human HLA-restricted antigen-presentation context (rat MHC, not human HLA, governs susceptibility in these models) — a genuine human-model-fidelity gap worth flagging explicitly if curated (candidate for a HUMAN_MODEL_MISMATCH discussion given rat MHC vs. human HLA-restricted epitope presentation, and adjuvant-driven vs. natural-infection induction).

Research applications: Lewis rat valvulitis models are used to dissect molecular-mimicry epitope specificity (M-protein vs. myosin vs. other candidate antigens), test candidate GAS vaccine constructs for cardiac cross-reactivity/safety (a major use case given the vaccine-safety concerns noted in §13), and study T-cell/antibody effector mechanisms of valve damage.

Other model systems: No robust zebrafish, Drosophila, C. elegans, or iPSC-organoid RHD model was identified in this search — the field remains centered on the Lewis rat immunization paradigm, with in vitro human valve endothelial/interstitial cell cross-reactivity assays as a complementary (non-whole-organism) system for mechanism dissection.

Summary Table — Suggested Ontology Term Anchors (verify all before curation)